ASCO 2021: Talazoparib Has Activity Comparable to Chemotherapy in Triple-Negative BRCA1/2 Mutated Breast Cancer
Results of phase II NEOTALA trial were promising
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.